# Xpert for Tuberculosis: Evaluating a New Diagnostic (XTEND)

Submission date 25/10/2011	<b>Recruitment status</b> No longer recruiting	<ul> <li>Prospectively registered</li> <li>Protocol</li> </ul>
Registration date 04/11/2011	<b>Overall study status</b> Completed	<ul> <li>[] Statistical analysis plan</li> <li>[X] Results</li> </ul>
Last Edited 30/03/2017	<b>Condition category</b> Infections and Infestations	Individual participant data

#### Plain English summary of protocol

Background and study aims

Tuberculosis (TB) is an infection that mainly affects the lungs, caused by a type of bacterium called Mycobacterium tuberculosis. The Xpert MTB/RIF is an automated diagnostic test that can identify Mycobacterium tuberculosis (MTB) DNA and resistance to the anti-tuberculosis drug rifampicin (RIF). The aim of this study is to find out whether using Xpert MTB/Rif reduces early mortality (death) in patients suspected of having TB, and its cost-effectiveness when used in a routine setting. The overall goal is to better understand how Xpert MTB/RIF should be best used when rolled out nationally in South Africa.

Who can participate? Patients aged 18 and over suspected of having TB

#### What does the study involve?

Participating laboratories are randomly allocated to one of two groups. Laboratories in one group test patients' sputum (phlegm) using a routine TB test (smear) and the other group use the new Xpert MTB/RIF test. Patients who are found to have multi-drug-resistant TB are given the appropriate treatment. After a 6-month follow-up period, the outcomes of the TB patients are compared and the costs and effectiveness of the MTB/RIF test are calculated.

What are the possible benefits and risks of participating? Not provided at time of registration

Where is the study run from? The Aurum Institute (South Africa)

When is the study starting and how long is it expected to run for? November 2011 to February 2014

Who is funding the study? Bill and Melinda Gates Foundation (USA) Who is the main contact? Prof. Gavin Churchyard gchurchyard@auruminstitute.org

## **Contact information**

**Type(s)** Scientific

**Contact name** Prof Gavin Churchyard

**Contact details** The Aurum Institute 29 Queens Road The Ridge Parktown Johannesburg South Africa 2193 +27 (0)10 590 1300 gchurchyard@auruminstitute.org

## Additional identifiers

EudraCT/CTIS number

**IRAS number** 

ClinicalTrials.gov number

**Secondary identifying numbers** XTEND - Xpert MTB/RIF - TB

# Study information

#### Scientific Title

Xpert MTB/RIF for diagnosis of tuberculosis: evaluating impact and cost-effectiveness in the routine roll-out in South Africa

Acronym XTEND

#### **Study objectives**

The overall goal of the project is to better understand how Xpert Mycobacterium tuberculosis/ resistance to rifampicin (MTB/RIF) should be best used under conditions of national roll-out by determining its effectiveness and cost effectiveness, and modelling these data to project the impact at population level in South Africa.

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

1. University of the Witwatersrand, 10/10/2011, ref: M110827

2. The National South African Department of Health (SANCTR, DoH), ref: DOH-27-1011-3849

3. The London School of Hygiene and Tropical Medicine, 07/10/2011, ref: 6041

4. University of Cape Town, 20/10/2010, ref: 363/2011

#### Study design

Pragmatic randomised trial

**Primary study design** Interventional

Secondary study design Randomised controlled trial

**Study setting(s)** Hospital

#### Study type(s)

Diagnostic

#### Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

#### Health condition(s) or problem(s) studied

Tuberculosis

#### Interventions

The intervention is the implementation of the GeneXpert MTB/RIF Diagnostic Instrument at randomised laboratories. The intervention laboratories will receive Xpert MTB/RIF, with one Xpert MTB/RIF test replacing the two smears at diagnosis. Patients that are sputum Xpert MTB /RIF positive (rifampicin-sensitive) will have a second sputum specimen collected for smear microscopy, to enable reporting of treatment outcomes according to World Health Organisation (WHO) definitions. Patients that are sputum Xpert MTB/RIF rifampicin resistant will be initiated on treatment for Multi-drug-resistant tuberculosis (MDR-TB) pending confirmation of drug susceptibility testing (DST) on positive cultures.

The control laboratories will continue to operate the existing standard of care, as per South African National Guideline, with two smears done for all TB suspects, and culture done if smear negative and symptomatic, if high MDR-risk.

Intervention Type Other

**Phase** Not Applicable

#### Primary outcome measure

The effectiveness of Xpert MTB/RIF in reducing early mortality in TB suspects

#### Secondary outcome measures

1. The primary default rate among newly diagnosed TB cases

2. The time from enrolment to start of treatment for drug susceptible TB and appropriate treatment for drug-resistant TB

3. The incremental cost per life saved and disability-adjusted life year (DALY) averted, including reductions in transmission of drug susceptible and drug resistant TB, from a provider and client perspective

Overall study start date

01/11/2011

**Completion date** 

28/02/2014

# Eligibility

#### Key inclusion criteria

1. The laboratories are placed in four Provinces geographically separate in serving a mix of clinics that have been allocated a GX16 Machine

2. Tuberculosis (TB) suspected participants contribute towards samples evaluated in the laboratories

3. Male and female participants

4. Aged 18 and above

Participant type(s)

Patient

Age group

Adult

Lower age limit 18 Years

**Sex** Both

**Target number of participants** 4400

#### Key exclusion criteria

- 1. The laboratories part of other TB Xpert MTB/RIF evaluations
- 2. Laboratories which already have an Xpert MTB/RIF instrument

3. Laboratories which do not comply with standard of care TB diagnostics

#### Date of first enrolment

01/11/2011

Date of final enrolment 28/02/2014

### Locations

**Countries of recruitment** South Africa

**Study participating centre The Aurum Institute** Johannesburg South Africa 2193

## Sponsor information

**Organisation** Bill and Melinda Gates Foundation (USA)

**Sponsor details** East Coast Office PO Box 6176 Ben Franklin Station Washington DC United States of America 20044

**Sponsor type** Charity

Website http://www.gatesfoundation.org

ROR https://ror.org/0456r8d26

## Funder(s)

Funder type Charity

Funder Name

Bill and Melinda Gates Foundation (USA)

**Alternative Name(s)** Bill & Melinda Gates Foundation, Gates Foundation, BMGF, B&MGF, GF

**Funding Body Type** Government organisation

**Funding Body Subtype** Trusts, charities, foundations (both public and private)

**Location** United States of America

## **Results and Publications**

#### Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

#### IPD sharing plan summary

Not provided at time of registration

#### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/08/2015		Yes	No